Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoChange Detected- Revision: v3.5.0 implemented. - Previous revision: v3.4.3 removed. - No visible changes to study details or page content.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No substantive content changes observed.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.4.2 is now displayed on the page, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision history updated: Revision: v3.4.1 was added and Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded a glossary toggle and updated study record metadata to include 'Last Update Submitted that Met QC Criteria' and a new revision label (Revision: v3.4.0). Removed or reformatted older QC-related text such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'.SummaryDifference0.2%

- Check70 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4, with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.